UK's National Institute for Clinical Excellence (NICE) Wants More Data on Bristol-Myers Squibb Company And Otsuka America Pharmaceutical, Inc. Schizophrenia Drug Abilify

LONDON, Sept 9 (Reuters) - Britain's healthcare cost watchdog said it was unable to recommend use of Bristol-Myers Squibb's (BMY.N) schizophrenia drug Abilify in children aged 15 to 17 and has asked for more information on its effectiveness.

Back to news